Final results from the Phase I study of MetMAb, a monovalent antagonist antibody to the receptor Met, dosed as single agent and in combination with bevacizumab in patients with advanced solid malignancies Other Scholarly Work

Moss, Rebecca A, Bothos, John G, Patel, Premal H et al. (2011). Final results from the Phase I study of MetMAb, a monovalent antagonist antibody to the receptor Met, dosed as single agent and in combination with bevacizumab in patients with advanced solid malignancies . CANCER RESEARCH, 71 10.1158/1538-7445.AM2011-4717

Industry Collaboration

cited authors

  • Moss, Rebecca A; Bothos, John G; Patel, Premal H; Peterson, Amy C; Eppler, Steve; Bai, Shuang; Nijem, Ihsan; Desnoyers, Luc; Kaur, Surinder; Zha, Jiping; Yu, Wei; Simpson, Joe; Ratain, Mark J; Tan, Antoinette R; Stein, Mark N; Mehnert, Janice M; Salgia, Ravi

authors

publication date

  • April 15, 2011

published in

keywords

  • Life Sciences & Biomedicine
  • Oncology
  • Science & Technology

Digital Object Identifier (DOI)

publisher

  • AMER ASSOC CANCER RESEARCH

volume

  • 71